Current therapies and new developments in NASH

Gut, Journal Year: 2022, Volume and Issue: 71(10), P. 2123 - 2134

Published: June 16, 2022

Non-alcoholic steatohepatitis is becoming the most important aetiology for advanced liver disease. There has been progress in field recent years and complexity of pathophysiology NASH better understood. Multiple non-invasive circulating imaging biomarkers have tested. The importance lifestyle recognised several drugs are being tested clinical trials. This review addresses challenges that healthcare professionals face management patients.

Language: Английский

---

Alcohol-Associated Hepatitis

New England Journal of Medicine, Journal Year: 2022, Volume and Issue: 387(26), P. 2436 - 2448

Published: Dec. 28, 2022

The authors review the epidemiology, pathophysiology, and treatment of alcohol-associated hepatitis, including evidence for glucocorticoids liver transplantation.

Language: Английский

---

High Prevalence of Advanced Liver Fibrosis Assessed by Transient Elastography Among U.S. Adults With Type 2 Diabetes

Diabetes Care, Journal Year: 2020, Volume and Issue: 44(2), P. 519 - 525

Published: Dec. 10, 2020

OBJECTIVE Type 2 diabetes mellitus (T2DM) is an important risk factor for the progression of metabolic liver disease to advanced fibrosis. Here, we provide estimate prevalence steatosis and fibrosis in U.S. adults with T2DM on basis transient elastography (TE) identify factors associated these conditions. RESEARCH DESIGN AND METHODS This a cross-sectional study participating 2017–2018 cycle National Health Nutrition Examination Survey who were evaluated by TE. Hepatic diagnosed median value controlled attenuation parameter (CAP) stiffness measurement (LSM), respectively. RESULTS Among 825 patients reliable TE examination results, 484 (53.7%) assessed using M probe 341 (46.3%) XL probe. Liver (CAP ≥274 dB/m), (LSM ≥9.7 kPa), cirrhosis ≥13.6 kPa) present 73.8% (95% CI 68.5%–78.5%), 15.4% 12.2%–19.0%), 7.7% 4.8%–11.9%) patients, The mean ± SE age was 63.7 2.2 years 57.8 1.6 years, In multivariable logistic regression model, BMI, non-Black race, ALT levels independent predictors steatosis; AST γ-glutamyltranspeptidase CONCLUSIONS Prevalence both high from United States obesity major factor. Our results support screening conditions among diabetes.

Language: Английский

---

Review article: the epidemiologic burden of non‐alcoholic fatty liver disease across the world

Alimentary Pharmacology & Therapeutics, Journal Year: 2022, Volume and Issue: 56(6), P. 942 - 956

Published: July 26, 2022

Summary Background The prevalence of non‐alcoholic fatty liver disease (NAFLD) is increasing in parallel with obesity and type 2 diabetes. Aim To review the global epidemiology NAFLD Methods We retrieved articles from PubMed using search terms NAFLD, epidemiology, prevalence, incidence, comorbidities. Results Over 250 were reviewed. In 2016, was 25%; this increased to >30% 2019. Prevalence Asia, Latin America Middle East‐North Africa (MENA) 30.8%, 34.5% 42.6%, respectively. age. Although higher men, post‐menopausal women similar. certain subpopulations, especially among obese those metabolic syndrome (MS). However, lean 11.2%. steatohepatitis (NASH) estimated between 2% 6% general population. Approximately 7% patients have advanced fibrosis; rates 21% 50% NASH. Overall mortality related 15–20 per 1000 person‐years, substantially NASH, components MS. Recent data suggest mortality/morbidity globally but awareness remains low healthcare providers. Conclusions poses a public health problem very high burden MENA America. Research needed better quantify full impact develop strategies improve risk stratification.

Language: Английский

---

Clinical profiles and mortality rates are similar for metabolic dysfunction-associated steatotic liver disease and non-alcoholic fatty liver disease

Journal of Hepatology, Journal Year: 2024, Volume and Issue: 80(5), P. 694 - 701

Published: Jan. 27, 2024

Language: Английский

---

Liver Transplantation 2023: Status Report, Current and Future Challenges

Clinical Gastroenterology and Hepatology, Journal Year: 2023, Volume and Issue: 21(8), P. 2150 - 2166

Published: April 20, 2023

Liver transplantation offers live-saving therapy for patients with complications of cirrhosis and stage T2 hepatocellular carcinoma. The demand organs far outstrips the supply, innovations aimed at increasing number usable deceased donors as well alternative donor sources are a major focus. etiologies shifting over time, more need among alcohol-associated liver disease nonalcoholic/metabolic fatty less viral hepatitis, although hepatitis B remains an important indication transplant in countries high endemicity. rise has brought attention to how selected strategies needed prevent recurrent disease. In this review, we present status report on most pressing topics future challenges.

Language: Английский

---

Epidemiological trends and trajectories of MAFLD-associated hepatocellular carcinoma 2002–2033: the ITA.LI.CA database

Gut, Journal Year: 2021, Volume and Issue: 72(1), P. 141 - 152

Published: Dec. 21, 2021

Metabolic dysfunction-associated fatty liver disease (MAFLD) represents a new inclusive definition of the whole spectrum diseases associated to metabolic disorders. The main objective this study was compare patients with MAFLD and non-MAFLD hepatocellular carcinoma (HCC) included in nationally representative cohort.We analysed 6882 consecutive HCC enrolled from 2002 2019 by 23 Italian Liver Cancer centres epidemiological future trends three subgroups: pure, single aetiology (S-MAFLD); mixed (metabolic others, M-MAFLD); HCC.MAFLD diagnosed majority (68.4%). proportion both total S-MAFLD significantly increased over time (from 50.4% 3.6% 2002-2003, 77.3% 28.9% 2018-2019, respectively, p<0.001). In Italy is expected overcome M-MAFLD about 6 years. Patients were older, more frequently men less cirrhotic clinically relevant portal hypertension surveillance-related diagnosis. They had large tumours extrahepatic metastases. After weighting, compared non-MAFLD, showed lower overall (p=0.026, p=0.004) HCC-related (p<0.001, for both) risk death. higher non-HCC-related death (p=0.006).The prevalence rapidly increasing cover HCC. Despite favourable cancer stage at diagnosis, have death, suggesting reduced aggressiveness.

Language: Английский

---

Non-invasive evaluation of response to obeticholic acid in patients with NASH: Results from the REGENERATE study

Journal of Hepatology, Journal Year: 2021, Volume and Issue: 76(3), P. 536 - 548

Published: Nov. 15, 2021

Language: Английский

---

From hepatitis A to E: A critical review of viral hepatitis

World Journal of Gastroenterology, Journal Year: 2021, Volume and Issue: 27(16), P. 1691 - 1715

Published: April 21, 2021

Viral infections affecting the liver have had an important impact on humanity, as they led to significant morbidity and mortality in patients with acute chronic infections. Once unknown etiology, discovery of viral agents triggered interest scientific community establish pathogenesis diagnostic modalities identify affected population. With rapid technological advances last centuries, controlling even curing became a possibility, large focus preventive medicine through vaccination. Hence, comprehensive understanding hepatitis A, B, C, D E is required by primary care physicians gastroenterologists provide these patients. The review article describes epidemiology, pathogenesis, clinical presentation, tools current medication regimens, upcoming treatment options role transplantation.

Language: Английский

---

Enhanced diagnosis of advanced fibrosis and cirrhosis in individuals with NAFLD using FibroScan-based Agile scores

Journal of Hepatology, Journal Year: 2022, Volume and Issue: 78(2), P. 247 - 259

Published: Nov. 12, 2022

Language: Английский

---